Indeed, our in ovo data confirmed this hypothesis in BAP1-deficient ccRCC cells treated with the Tat-BECN1 peptide, as tumor growth was significantly compromised compared to the Tat-scrambled peptide control. The gene discussed is TAT; the disease is nonpapillary renal cell carcinoma.